Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03766126 · ClinicalTrials.gov registry record · Phase 1

Lentivirally Redirected CD123 Autologous T Cells in AML

A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by University of Pennsylvania.

Active
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT03766126 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 22 participants, below the 58-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03766126, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is active but no longer recruiting, sponsored by University of Pennsylvania.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.

Conditions Studied

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia, Adult

Interventions

  • BIOLOGICAL CART123 cells; cyclophosphamide; fludarabine

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-12-06
Est. Completion 2033-12-03
Phase Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03766126

The ClinicalTrials.gov registry entry for NCT03766126 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (62% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 1 intervention - of which CART123 cells; cyclophosphamide; fludarabine is the first listed.

NCT03766126 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03766126 about?

NCT03766126 is a clinical study titled "Lentivirally Redirected CD123 Autologous T Cells in AML". Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML...

What is the current status of trial NCT03766126?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-12-06. Estimated completion is 2033-12-03.

What conditions does trial NCT03766126 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Adult.

What interventions are being tested in trial NCT03766126?

The interventions under investigation include: CART123 cells; cyclophosphamide; fludarabine (BIOLOGICAL).

Who is sponsoring clinical trial NCT03766126?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03766126 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia, in Relapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia, in Relapse

All registered trials for this condition

Acute Myeloid Leukemia Refractory

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.